The 36-month beta value for OCX is at 0.90. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for OCX is 13.18M, and currently, shorts hold a 2.43% of that float. The average trading volume for OCX on January 23, 2025 was 82.28K shares.
OCX) stock’s latest price update
Oncocyte Corporation (NASDAQ: OCX)’s stock price has dropped by -7.55 in relation to previous closing price of 2.12. Nevertheless, the company has seen a loss of -8.84% in its stock price over the last five trading days. globenewswire.com reported 2025-01-08 that Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer.
OCX’s Market Performance
Oncocyte Corporation (OCX) has experienced a -8.84% fall in stock performance for the past week, with a -10.91% drop in the past month, and a -37.38% drop in the past quarter. The volatility ratio for the week is 6.21%, and the volatility levels for the past 30 days are at 8.32% for OCX. The simple moving average for the past 20 days is -10.81% for OCX’s stock, with a -30.27% simple moving average for the past 200 days.
Analysts’ Opinion of OCX
Stephens gave a rating of “Overweight” to OCX, setting the target price at $3.10 in the report published on January 07th of the previous year.
OCX Trading at -18.44% from the 50-Day Moving Average
After a stumble in the market that brought OCX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.68% of loss for the given period.
Volatility was left at 8.32%, however, over the last 30 days, the volatility rate increased by 6.21%, as shares sank -11.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.99% lower at present.
During the last 5 trading sessions, OCX fell by -8.84%, which changed the moving average for the period of 200-days by -33.33% in comparison to the 20-day moving average, which settled at $2.20. In addition, Oncocyte Corporation saw -17.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCX starting from SMITH PATRICK W, who purchase 10,386 shares at the price of $2.15 back on Jan 14 ’25. After this action, SMITH PATRICK W now owns 1,789,958 shares of Oncocyte Corporation, valued at $22,323 using the latest closing price.
SMITH PATRICK W, the 10% Owner of Oncocyte Corporation, purchase 5,669 shares at $2.08 during a trade that took place back on Jan 13 ’25, which means that SMITH PATRICK W is holding 1,779,572 shares at $11,792 based on the most recent closing price.
Stock Fundamentals for OCX
Current profitability levels for the company are sitting at:
- -40.81 for the present operating margin
- -0.47 for the gross margin
The net margin for Oncocyte Corporation stands at -60.85. The total capital return value is set at -0.47. Equity return is now at value -165.32, with -56.84 for asset returns.
Based on Oncocyte Corporation (OCX), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -4.99. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is -135.19.
Currently, EBITDA for the company is -23.12 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 47.43. The receivables turnover for the company is 3.39for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.49.
Conclusion
In conclusion, Oncocyte Corporation (OCX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
